NEW YORK (GenomeWeb) – Diagnostics developer Guardant Health has inked a deal with molecular data interpretation firm N-of-One to provide decision support services for its Guardant360 test.

The diagnostic uses next-generation sequencing to analyze cell-free DNA, tumor fragments shed into the blood at low concentrations. The test can be used to gauge genetic alterations driving various tumor types and can be used by doctors to inform personalized medicine strategies for patients or guide them to clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.